Has the patient ever been treated with 180 mg of Adderall (mixed amphetamine salts) instant‑release?

180 mg Daily Dose of Adderall IR is Extraordinarily High and Exceeds Standard Clinical Practice

No, a patient should not be on 180 mg of Adderall instant release daily—this dose is far beyond FDA-approved dosing ranges and established clinical guidelines. This represents a potentially dangerous dose that raises serious concerns about misuse, diversion, or inappropriate prescribing.

FDA-Approved Dosing Parameters

The FDA label for Adderall (mixed amphetamine salts) provides clear dosing guidance 1:

• For ADHD in children 6+ years: Starting dose 5 mg once or twice daily, with increases of 5 mg at weekly intervals. Doses rarely exceed 40 mg/day.
• For ADHD in adolescents and adults: While the label doesn't specify an absolute maximum, typical therapeutic doses range from 20-60 mg/day divided into 2-3 doses.
• For narcolepsy (ages 6+): Starting dose 10 mg daily, with increases of 10 mg at weekly intervals. Typical range is 5-60 mg/day.

180 mg daily represents 3-9 times the typical maximum therapeutic dose.

Clinical Evidence and Safety Concerns

Research on Adderall efficacy demonstrates therapeutic benefit at much lower doses. A controlled trial in adults with ADHD showed significant improvement at an average dose of 54 mg/day (administered as 30 mg twice daily), with 70% of patients responding versus 7% on placebo 2. This dose—already considered robust—is less than one-third of 180 mg daily.

The FDA label explicitly warns about 1:

• High potential for abuse, misuse, and addiction leading to overdose and death
• Increased risk with higher doses or non-approved routes of administration
• Sudden death in patients with serious heart disease
• Cardiovascular effects including increased blood pressure and heart rate
• Psychiatric problems including new or worsening psychosis, mania, and behavioral disturbances

Red Flags and Clinical Action

A dose of 180 mg daily should trigger immediate investigation:

1. Verify the prescription: Confirm this is not a documentation error or misunderstanding (e.g., confusing monthly supply with daily dose)
2. Assess for diversion: This dose strongly suggests medication is being diverted, sold, or shared
3. Evaluate for substance use disorder: The patient may have developed tolerance and addiction requiring specialized addiction treatment rather than continued stimulant therapy
4. Screen for misuse patterns: Check prescription drug monitoring programs (PDMPs) for doctor shopping or concurrent controlled substance prescriptions
5. Consider psychiatric consultation: If legitimately prescribed, this represents highly unusual practice requiring specialist oversight

Appropriate Clinical Response

If you encounter a patient reporting this dose, do not continue prescribing at this level. Instead:

• Conduct comprehensive substance use assessment
• Review all controlled substance prescriptions through PDMP
• Consider urine drug screening
• Refer to addiction medicine or psychiatry for evaluation
• If ADHD treatment is genuinely needed, restart at evidence-based doses (typically 20-60 mg/day) with close monitoring
• Document thoroughly and consider reporting concerns about the original prescriber if this represents inappropriate prescribing

The standard of care for ADHD treatment with stimulants involves starting low, titrating gradually, and using the minimum effective dose 3. Doses of 180 mg daily fall far outside evidence-based practice and raise serious safety and regulatory concerns.